drugset / Trial / NCT04096326
AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the safety and efficacy of AGN-151586 over a range of doses for the treatment of moderate to severe glabellar lines (GL).
Timeline
- Start
- 2019-09-26
- Primary completion
- 2020-09-09
- Completion
- 2020-09-09
Outcome
Met primary endpoint
registry analysis (superiority test); Cohort 1: Placebo vs Cohort 1: AGN-151586; p = 0.0096; Rate difference 40.6 (95% CI 23.6 to 57.6); NCT04096326 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AGN-151586 | Unknown | — | Intramuscular |
Indications
No indication recorded.